Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vedolizumab IV as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
NCT04779320Phase 3Recruiting
- Sponsor
- Takeda
- Start
- Feb 2022
- Primary completion
- Sep 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 18
01
Overview
A Phase 3 trial of vedolizumab in Crohn's disease, sponsored by Takeda. Started Feb 2022; status: recruiting.
02
Drugs
vedolizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT04779320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04779320.